Interpace Diagnostics Group (NASDAQ:IDXG) Files An 8-K Entry into a Material Definitive Agreement

Item 1.01 of the Original 8-K. The full text of the press release
is attached as Exhibit 99.1 to this Current Report on Form 8-K
and is incorporated into this Item 7.01 by reference. This
information is not deemed to be filed for the purposes of Section
18 of the Securities Exchange Act of 1934, as amended, and is not
incorporated by reference into any Securities Act registration
statements.

Item 9.01.Financial Statements and Exhibits

(d)Exhibits

About Interpace Diagnostics Group (NASDAQ:IDXG)

Interpace Diagnostics Group, Inc., formerly PDI, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The Company operates through molecular diagnostics segment. It offers molecular tests, such as PancraGen, which is a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy, and ThyraMIR, which assesses thyroid nodules risk of malignancy utilizing a gene expression assay. Through its molecular diagnostics business, the Company provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer.

Interpace Diagnostics Group (NASDAQ:IDXG) Recent Trading Information

Interpace Diagnostics Group (NASDAQ:IDXG) closed its last trading session down -0.340 at 0.770 with 10,161,170 shares trading hands.